PD-L1-positive tumors may indicate immune active tumors that can be a response to anti-PD-1 and/or PD-L1 therapies because they are correlated with the poor prognosis of many of these malignancies, including lung adenocarcinoma, melanoma, and refractory Hodgkin's lymphoma.[4–7] However, the prognostic role of PD-L1 remains unclear. The gene discussed is PDCD1; the disease is melanoma.